REG - Redx Pharma plc - Share Purchases by Directors

Redx PharmaAnnouncement

23/12/2020 09:00

RNS Number : 6582J
  
Redx Pharma plc
  
23 December 2020
  
 

REDX PHARMA PLC
("Redx" or "the Company")
 
Share Purchases by Directors
 
Alderley Park, 23 December 2020 - Redx Pharma (AIM:REDX), the drug discovery and development Group focused on cancer and fibrosis, announces that it has been notified that Lisa Anson, Chief Executive Officer, has on Tuesday 22 December acquired 39,998 Redx ordinary shares at the following prices: 
 



Number of Ordinary shares purchased


Price per share (pence)




39,998


50p



 
 
Following this, Mrs Anson will hold 129,284 ordinary shares in the Company, representing 0.05 per cent. of the issued share capital.
 
 
-Ends-
 
For further information, please contact:
 



Redx Pharma Plc


T: +44 1625 469 918




Lisa Anson, Chief Executive Officer
James Mead, Chief Financial Officer


 




 


 




SPARK Advisory Partners (Nominated Advisor)


 T: +44 203 368 3550




Matt Davis/ Adam Dawes


 




 


 




WG Partners LLP (Broker)


T: +44 20 3705 9330




Claes Spång/ Chris Lee/ David Wilson


 




 


 




 








FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin


 



 
About Redx Pharma Plc 
Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
 



Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014




1


Details of the person discharging managerial responsibilities/person closely associated




a.


Name


Lisa Anson




2


Reason for notification


 
 
 




a.


Position/Status


Chief Executive




b.


Initial notification/
Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.


Name


Redx Pharma Plc




b.


LEI


213800HMS4EBXO589Y37




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.


Description of the financial instrument, type of instrument



Identification Code


Ordinary Shares of 1p each





ISIN: GB00BSNB6S51




b.


Nature of the transaction


Purchase




c.


Price(s) and volume(s)


39,998 at 50 pence per share
 




d.


Aggregated information
- Aggregated Volume
- Price


39,998 at 50 pence per share




e.


Date of the transaction


22/12/20




f.


Place of the transaction


Outside of trading venue



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHFIFVTFVLVFII